Skip to main content
Fig. 4 | Clinical Epigenetics

Fig. 4

From: Epigenome-wide association study for lifetime estrogen exposure identifies an epigenetic signature associated with breast cancer risk

Fig. 4

Time to diagnosis and the association between the MI and breast cancer risk. Matched case-control pairs were stratified on median time to diagnosis in EPIC-Italy HM450K data (dataset 2) and in the four study cohorts included in the meta-analysis. The association between the MI and breast cancer risk was analyzed in the two groups. a The MI was significantly associated with breast cancer risk in EPIC-Italy pairs with a shorter time to diagnosis (n = 81 pairs, OR = 1.47, 95% CI 1.12–1.93, P = 0.005). b The MI was significantly associated with breast cancer risk in EPIC-Italy pairs with a longer time to diagnosis (n = 81 pairs, OR = 1.84, 95% CI 1.30–2.61, P = 0.001). c The combined meta-analysis including pairs with shorter time to diagnosis showed no significant association between the MI and breast cancer risk (OR = 1.03, 95% CI 0.98–1.08, P = 0.241). d The combined meta-analysis including pairs with shorter time to diagnosis showed no significant association between the MI and breast cancer risk (OR = 1.05, 95% CI 1.01–1.10, P = 0.021). The log odds ratios were combined in the meta-analyses using restricted-maximum likelihood model. ORs were adjusted for age, BMI, alcohol consumption, and smoking duration (all variables reported at recruitment) and WBC composition

Back to article page